SIMILAR PATTERNS OF AMINO ACIDS FOR 4AGD_A_B49A2000_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 31 LYS A 33 VAL A 64 PHE A 82 CYH A 83 LEU A 133	None	0.57A	4agdA-1h4lA: 16.9	4agdA-1h4lA: 26.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 267 ALA A 288 VAL A 318 PHE A 336 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 ( 4.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.35A	4agdA-1opkA: 29.8	4agdA-1opkA: 28.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 ALA A 642 LYS A 644 VAL A 675 CYH A 694 GLY A 697 LEU A 818 CYH A 828	None	0.65A	4agdA-1rjbA: 41.1	4agdA-1rjbA: 47.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LYS A 644 VAL A 675 GLY A 697 LEU A 818 CYH A 828 PHE A 830	None	1.26A	4agdA-1rjbA: 41.1	4agdA-1rjbA: 47.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 78 ALA A 99 LYS A 101 GLY A 153 LEU A 201 CYH A 211	ATP A 535 (-3.9A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A) ATP A 535 ( 4.5A)	1.01A	4agdA-1s9iA: 21.0	4agdA-1s9iA: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 78 ALA A 99 VAL A 131 GLY A 153 LEU A 201 CYH A 211	ATP A 535 (-3.9A) ATP A 535 (-3.6A) 5EA A1001 (-4.5A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A) ATP A 535 ( 4.5A)	0.84A	4agdA-1s9iA: 21.0	4agdA-1s9iA: 25.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 389 VAL A 419 PHE A 437 GLY A 441 LEU A 489	None	0.51A	4agdA-1snxA: 29.7	4agdA-1snxA: 32.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 595 ALA A 621 LYS A 623 VAL A 654 CYH A 673 GLY A 676 LEU A 799 CYH A 809 PHE A 811	STI A 3 ( 3.8A) STI A 3 (-3.5A) STI A 3 (-3.7A) STI A 3 (-4.3A) STI A 3 (-4.5A) STI A 3 ( 3.8A) STI A 3 (-4.4A) STI A 3 (-4.5A) STI A 3 (-3.6A)	0.65A	4agdA-1t46A: 33.3	4agdA-1t46A: 49.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	LEU A 344 ALA A 367 VAL A 399 GLY A 420 LEU A 468	STU A 100 (-3.8A) STU A 100 (-3.2A) None STU A 100 (-3.5A) STU A 100 (-4.5A)	0.41A	4agdA-1u59A: 30.5	4agdA-1u59A: 30.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 15 ALA A 36 LYS A 38 VAL A 68 CYH A 87 GLY A 90 LEU A 137	HYM A 400 (-4.2A) HYM A 400 (-3.5A) HYM A 400 (-3.2A) HYM A 400 (-4.8A) HYM A 400 (-4.2A) None HYM A 400 (-4.5A)	0.58A	4agdA-1zltA: 20.3	4agdA-1zltA: 23.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	LEU X 17 ALA X 37 VAL X 67 GLY X 88 LEU X 137	STU X 902 (-3.8A) STU X 902 (-3.1A) None STU X 902 (-3.5A) STU X 902 (-4.4A)	0.40A	4agdA-2dq7X: 30.4	4agdA-2dq7X: 32.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 273 ALA A 293 VAL A 323 PHE A 340 GLY A 344 LEU A 393	QUE A 1 (-3.9A) QUE A 1 (-3.5A) None QUE A 1 (-4.2A) QUE A 1 (-3.0A) QUE A 1 (-4.4A)	0.58A	4agdA-2hckA: 27.8	4agdA-2hckA: 30.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 251 ALA A 271 VAL A 301 PHE A 318 GLY A 322 LEU A 371	1BM A 499 ( 3.7A) 1BM A 499 (-3.6A) None 1BM A 499 (-4.1A) 1BM A 499 (-3.5A) 1BM A 499 (-4.4A)	0.63A	4agdA-2hk5A: 29.9	4agdA-2hk5A: 35.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hw6	MAP KINASE-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 55 ALA A 76 GLY A 130 LEU A 177 CYH A 190	None	0.39A	4agdA-2hw6A: 19.9	4agdA-2hw6A: 24.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 269 LYS A 271 VAL A 299 GLY A 321 LEU A 370 PHE A 382	GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-4.6A) None GIN A 600 (-4.7A) GIN A 600 (-4.0A)	0.80A	4agdA-2hz0A: 30.7	4agdA-2hz0A: 35.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 269 VAL A 299 PHE A 317 GLY A 321 LEU A 370 PHE A 382	GIN A 600 (-3.1A) GIN A 600 (-4.6A) GIN A 600 (-4.3A) None GIN A 600 (-4.7A) GIN A 600 (-4.0A)	0.65A	4agdA-2hz0A: 30.7	4agdA-2hz0A: 35.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 248 ALA A 269 LYS A 271 VAL A 299 GLY A 321 LEU A 370	GIN A 600 ( 4.6A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-4.6A) None GIN A 600 (-4.7A)	0.62A	4agdA-2hz0A: 30.7	4agdA-2hz0A: 35.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 248 ALA A 269 VAL A 299 PHE A 317 GLY A 321 LEU A 370	GIN A 600 ( 4.6A) GIN A 600 (-3.1A) GIN A 600 (-4.6A) GIN A 600 (-4.3A) None GIN A 600 (-4.7A)	0.47A	4agdA-2hz0A: 30.7	4agdA-2hz0A: 35.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2j0j	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF00373 (FERM_M) PF07714 (Pkinase_Tyr)	5	ALA A 452 VAL A 484 CYH A 502 GLY A 505 LEU A 553	4ST A1687 (-3.3A) None 4ST A1687 (-4.1A) 4ST A1687 (-3.2A) 4ST A1687 (-4.4A)	0.53A	4agdA-2j0jA: 32.5	4agdA-2j0jA: 22.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2jkm	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	ALA A 452 LYS A 454 VAL A 484 CYH A 502 GLY A 505 LEU A 553	BII A1687 (-3.5A) BII A1687 (-2.9A) None BII A1687 (-4.1A) BII A1687 (-3.6A) BII A1687 (-4.2A)	0.64A	4agdA-2jkmA: 31.3	4agdA-2jkmA: 31.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 588 ALA A 614 LYS A 616 VAL A 647 CYH A 666 GLY A 669 LEU A 785	None	0.48A	4agdA-2ogvA: 27.4	4agdA-2ogvA: 48.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	LEU A 344 ALA A 367 LYS A 369 VAL A 399 GLY A 420 LEU A 468	ANP A 615 (-4.4A) ANP A 615 (-3.3A) ANP A 615 (-3.1A) None ANP A 615 ( 3.9A) ANP A 615 (-4.7A)	0.87A	4agdA-2ozoA: 22.4	4agdA-2ozoA: 23.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 487 ALA A 515 LYS A 517 VAL A 564 GLY A 570 LEU A 633	None	0.48A	4agdA-2psqA: 34.3	4agdA-2psqA: 50.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 68 ALA A 92 VAL A 125 PHE A 143 GLY A 147 LEU A 194	STU A 1 (-3.8A) STU A 1 (-3.3A) None STU A 1 (-4.6A) STU A 1 ( 3.9A) STU A 1 (-4.6A)	0.47A	4agdA-2z7rA: 16.1	4agdA-2z7rA: 27.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2z8c	INSULIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	LEU A1002 ALA A1028 LYS A1030 VAL A1060 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None S91 A 1 (-3.3A)	0.55A	4agdA-2z8cA: 29.4	4agdA-2z8cA: 36.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	LEU A 253 ALA A 273 LYS A 275 VAL A 303 PHE A 321 GLY A 325 LEU A 374	None	0.83A	4agdA-2zv7A: 29.9	4agdA-2zv7A: 34.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 487 ALA A 515 LYS A 517 VAL A 564 GLY A 570 LEU A 633	M33 A1996 (-4.0A) M33 A1996 (-3.3A) M33 A1996 ( 4.5A) None M33 A1996 ( 4.8A) M33 A1996 (-4.5A)	0.63A	4agdA-3b2tA: 33.6	4agdA-3b2tA: 49.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 484 ALA A 512 VAL A 561 GLY A 567 LEU A 630 PHE A 489	C4F A 1 ( 3.9A) C4F A 1 (-3.3A) C4F A 1 ( 4.8A) None C4F A 1 (-4.6A) C4F A 1 (-3.7A)	0.78A	4agdA-3c4fA: 33.5	4agdA-3c4fA: 54.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3dko	EPHRIN TYPE-A RECEPTOR 7 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	ALA A 663 VAL A 695 PHE A 713 GLY A 717 LEU A 765 PHE A 777	IHZ A1001 (-3.3A) IHZ A1001 ( 4.9A) None IHZ A1001 ( 3.9A) IHZ A1001 (-4.6A) IHZ A1001 (-4.7A)	0.61A	4agdA-3dkoA: 31.1	4agdA-3dkoA: 33.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3fzp	PROTEIN TYROSINE KINASE 2 BETA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 431 ALA A 455 LYS A 457 VAL A 487 GLY A 508 LEU A 556	AGS A 999 ( 4.4A) AGS A 999 (-3.6A) AGS A 999 (-2.5A) None None AGS A 999 (-4.5A)	0.80A	4agdA-3fzpA: 30.5	4agdA-3fzpA: 32.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 833 ALA A 859 LYS A 861 VAL A 892 VAL A 909 CYH A 912 LEU A1029 CYH A1039 PHE A1041	8ST A2001 ( 4.7A) 8ST A2001 ( 3.8A) 8ST A2001 (-4.0A) 8ST A2001 ( 4.7A) 8ST A2001 (-4.1A) 8ST A2001 (-3.8A) None 8ST A2001 (-4.2A) 8ST A2001 ( 3.7A)	0.68A	4agdA-3hngA: 41.4	4agdA-3hngA: 67.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 833 ALA A 859 VAL A 892 VAL A 909 CYH A 912 GLY A 915 LEU A1029 CYH A1039 PHE A1041	8ST A2001 ( 4.7A) 8ST A2001 ( 3.8A) 8ST A2001 ( 4.7A) 8ST A2001 (-4.1A) 8ST A2001 (-3.8A) None None 8ST A2001 (-4.2A) 8ST A2001 ( 3.7A)	0.60A	4agdA-3hngA: 41.4	4agdA-3hngA: 67.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mi9	CELL DIVISION PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 46 LYS A 48 VAL A 79 PHE A 105 CYH A 106 LEU A 156	None	0.62A	4agdA-3mi9A: 21.4	4agdA-3mi9A: 25.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	5	LEU A 192 ALA A 213 VAL A 247 GLY A 269 LEU A 318	AMP A 577 ( 4.3A) AMP A 577 (-3.4A) None None AMP A 577 (-4.8A)	0.52A	4agdA-3nyoA: 20.9	4agdA-3nyoA: 22.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q4t	ACTIVIN RECEPTOR TYPE-2A (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 217 LYS A 219 PHE A 269 GLY A 273 LEU A 329	TAK A 2 (-3.5A) TAK A 2 (-2.9A) TAK A 2 (-4.3A) TAK A 2 (-3.6A) TAK A 2 (-4.6A)	0.53A	4agdA-3q4tA: 23.4	4agdA-3q4tA: 24.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q5i	PROTEIN KINASE (Plasmodium berghei)	PF00069 (Pkinase) PF13499 (EF-hand_7)	5	LEU A 63 ALA A 84 PHE A 146 GLY A 150 LEU A 197	ANP A1634 ( 4.3A) ANP A1634 (-3.6A) ANP A1634 (-4.8A) None ANP A1634 (-4.4A)	0.55A	4agdA-3q5iA: 19.2	4agdA-3q5iA: 22.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	LEU A 423 ALA A 443 VAL A 473 GLY A 495 LEU A 543	PP2 A 1 (-4.1A) PP2 A 1 (-3.2A) None PP2 A 1 ( 4.2A) PP2 A 1 (-4.6A)	0.47A	4agdA-3sxsA: 29.0	4agdA-3sxsA: 32.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	LEU A 484 ALA A 512 VAL A 561 GLY A 567 LEU A 630	07J A 1 ( 4.3A) 07J A 1 (-3.5A) 07J A 1 (-4.7A) 07J A 1 (-3.7A) 07J A 1 ( 4.4A)	0.51A	4agdA-3tt0A: 34.6	4agdA-3tt0A: 50.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	LEU A 544 ALA A 570 VAL A 601 GLY A 623 LEU A 686	0F4 A 902 ( 4.2A) 0F4 A 902 (-3.2A) None 0F4 A 902 (-3.4A) 0F4 A 902 (-4.5A)	0.52A	4agdA-3v5qA: 26.6	4agdA-3v5qA: 32.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 840 ALA A 866 VAL A 899 VAL A 916 PHE A 918 CYH A 919 GLY A 922 LEU A1035 CYH A1045	4TT A2001 ( 4.0A) 4TT A2001 (-3.5A) None None 4TT A2001 (-4.5A) 4TT A2001 (-4.3A) 4TT A2001 (-3.7A) 4TT A2001 (-4.8A) None	0.37A	4agdA-3vidA: 38.8	4agdA-3vidA: 85.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 75 ALA A 96 LYS A 98 GLY A 150 LEU A 198 CYH A 208	ANP A 401 (-3.8A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A) CHU A 403 ( 3.7A)	1.29A	4agdA-3wigA: 16.1	4agdA-3wigA: 22.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 840 ALA A 866 VAL A 899 VAL A 916 PHE A 918 CYH A 919 GLY A 922 LEU A1035 CYH A1045	LEV A1201 ( 3.8A) LEV A1201 (-3.5A) None LEV A1201 ( 4.6A) LEV A1201 (-4.7A) LEV A1201 (-4.1A) LEV A1201 (-3.6A) LEV A1201 (-4.8A) GOL A1210 ( 3.3A)	0.33A	4agdA-3wzdA: 37.6	4agdA-3wzdA: 100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 31 LYS A 33 VAL A 64 CYH A 83 LEU A 133 CYH A 143	D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None D15 A 500 (-4.3A) D15 A 500 (-4.5A) D15 A 500 ( 4.0A)	0.61A	4agdA-4aguA: 22.0	4agdA-4aguA: 25.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4aw5	EPHRIN TYPE-B RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 121 LYS A 123 PHE A 171 GLY A 175 LEU A 223	30K A1365 (-3.2A) 30K A1365 (-3.8A) 30K A1365 (-4.4A) 30K A1365 (-3.5A) 30K A1365 (-4.5A)	0.54A	4agdA-4aw5A: 26.3	4agdA-4aw5A: 29.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 42 ALA A 63 VAL A 94 PHE A 112 CYH A 113 GLY A 116 LEU A 164	XZN A1317 (-3.6A) XZN A1317 (-3.5A) XZN A1317 (-4.4A) XZN A1317 (-4.5A) XZN A1317 (-3.7A) XZN A1317 ( 3.7A) XZN A1317 (-4.7A)	0.70A	4agdA-4bc6A: 19.9	4agdA-4bc6A: 25.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	5	LEU A 663 ALA A 684 VAL A 721 GLY A 743 LEU A 789	AGS A1985 (-4.2A) AGS A1985 (-3.5A) None None AGS A1985 (-4.8A)	0.43A	4agdA-4crsA: 19.9	4agdA-4crsA: 23.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4eut	SERINE/THREONINE-PRO TEIN KINASE TBK1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 15 ALA A 36 VAL A 68 PHE A 88 CYH A 89 GLY A 92	BX7 A 401 (-3.7A) BX7 A 401 (-3.4A) None BX7 A 401 ( 4.6A) BX7 A 401 (-4.1A) BX7 A 401 (-3.5A)	0.40A	4agdA-4eutA: 12.0	4agdA-4eutA: 22.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4euu	SERINE/THREONINE-PRO TEIN KINASE TBK1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 15 ALA A 36 VAL A 68 PHE A 88 CYH A 89 GLY A 92	BX7 A 401 (-3.9A) BX7 A 401 (-3.4A) None BX7 A 401 ( 4.6A) BX7 A 401 (-4.1A) BX7 A 401 (-3.3A)	0.41A	4agdA-4euuA: 21.2	4agdA-4euuA: 24.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 377 ALA A 400 LYS A 402 VAL A 433 GLY A 454 LEU A 501	0SB A 701 ( 3.9A) 0SB A 701 (-3.3A) 0SB A 701 ( 4.8A) None 0SB A 701 (-3.5A) 0SB A 701 (-4.4A)	0.83A	4agdA-4f4pA: 29.4	4agdA-4f4pA: 34.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fie	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	PF00069 (Pkinase) PF00786 (PBD)	6	ALA A 348 LYS A 350 VAL A 379 PHE A 397 GLY A 401 LEU A 447	ANP A1001 (-3.6A) ANP A1001 (-3.0A) None ANP A1001 ( 4.6A) None ANP A1001 (-4.7A)	0.72A	4agdA-4fieA: 20.7	4agdA-4fieA: 25.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	5	LEU A 377 ALA A 400 VAL A 433 GLY A 454 LEU A 501	ANP A 701 ( 4.6A) ANP A 701 (-3.3A) ANP A 701 (-4.8A) ANP A 701 ( 4.2A) ANP A 701 (-4.5A)	0.49A	4agdA-4fl3A: 28.5	4agdA-4fl3A: 23.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A1122 ALA A1148 LYS A1150 VAL A1180 GLY A1202 LEU A1256	0UV A1501 (-3.8A) 0UV A1501 (-3.4A) 0UV A1501 (-3.7A) 0UV A1501 ( 4.9A) 0UV A1501 (-3.6A) 0UV A1501 (-4.6A)	0.74A	4agdA-4fodA: 29.7	4agdA-4fodA: 33.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fr4	SERINE/THREONINE-PRO TEIN KINASE 32A (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 50 VAL A 84 VAL A 100 GLY A 106 LEU A 153	STU A 401 (-3.2A) None None STU A 401 ( 3.7A) STU A 401 (-4.7A)	0.41A	4agdA-4fr4A: 20.2	4agdA-4fr4A: 23.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	LEU A 828 ALA A 853 VAL A 884 GLY A 908 LEU A 956	19S A1201 (-3.9A) 19S A1201 (-3.3A) None 19S A1201 ( 3.8A) 19S A1201 (-4.5A)	0.42A	4agdA-4hviA: 29.2	4agdA-4hviA: 31.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4idt	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 406 ALA A 427 VAL A 453 GLY A 475 LEU A 522 CYH A 533	T28 A 701 (-3.8A) T28 A 701 (-3.0A) None T28 A 701 ( 3.0A) T28 A 701 (-3.9A) T28 A 701 (-3.7A)	0.80A	4agdA-4idtA: 21.2	4agdA-4idtA: 26.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jlc	SERINE/THREONINE-PRO TEIN KINASE TBK1 (Mus musculus)	PF00069 (Pkinase)	6	LEU A 15 ALA A 36 VAL A 68 PHE A 88 CYH A 89 GLY A 92	SU6 A 701 (-3.6A) SU6 A 701 (-3.4A) None SU6 A 701 (-4.0A) SU6 A 701 (-3.8A) SU6 A 701 (-3.8A)	0.42A	4agdA-4jlcA: 17.9	4agdA-4jlcA: 20.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jxf	SERINE/THREONINE-PRO TEIN KINASE PLK4 (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 18 ALA A 39 CYH A 92 GLY A 95 LEU A 143	631 A 301 (-3.4A) 631 A 301 (-3.3A) 631 A 301 (-4.5A) 631 A 301 ( 3.7A) 631 A 301 (-4.0A)	0.38A	4agdA-4jxfA: 18.1	4agdA-4jxfA: 23.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	LEU A 478 ALA A 506 VAL A 555 GLY A 561 LEU A 624	ACP A 801 (-3.8A) ACP A 801 (-3.3A) ACP A 801 (-4.7A) ACP A 801 ( 4.6A) ACP A 801 (-4.4A)	0.49A	4agdA-4k33A: 34.2	4agdA-4k33A: 51.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ks8	SERINE/THREONINE-PRO TEIN KINASE PAK 6 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 434 VAL A 465 PHE A 483 GLY A 487 LEU A 533	B49 A 701 (-3.2A) None B49 A 701 (-4.3A) B49 A 701 ( 3.7A) B49 A 701 (-4.5A)	0.43A	4agdA-4ks8A: 21.9	4agdA-4ks8A: 27.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4l01	TYROSINE-PROTEIN KINASE JAK1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 589 LYS A 622 VAL A 651 PHE A 669 GLY A 673 LEU A 721	None	0.77A	4agdA-4l01A: 26.0	4agdA-4l01A: 24.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	LEU A 273 ALA A 293 LYS A 295 VAL A 323 GLY A 344 LEU A 393	VGG A 601 (-3.2A) VGG A 601 (-3.5A) VGG A 601 (-3.8A) VGG A 601 ( 4.8A) VGG A 601 ( 3.2A) VGG A 601 (-4.5A)	0.83A	4agdA-4lggA: 27.6	4agdA-4lggA: 34.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 46 ALA A 67 LYS A 69 VAL A 99 CYH A 126 GLY A 128 LEU A 180 CYH A 190	SIN A 401 ( 3.9A) SIN A 401 ( 3.7A) None None SIN A 401 (-4.3A) SIN A 401 (-3.5A) SIN A 401 ( 4.5A) None	0.82A	4agdA-4o38A: 19.8	4agdA-4o38A: 24.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oav	PROTEIN (RNASE L) (Homo sapiens)	PF00069 (Pkinase) PF06479 (Ribonuc_2-5A) PF12796 (Ank_2) PF13857 (Ank_5)	5	ALA B 390 VAL B 418 VAL B 434 CYH B 437 LEU B 492	ACP B 801 (-3.2A) None ACP B 801 (-4.8A) ACP B 801 (-4.5A) ACP B 801 (-4.5A)	0.55A	4agdA-4oavB: 17.0	4agdA-4oavB: 19.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	5	LEU A 627 ALA A 648 VAL A 685 GLY A 707 LEU A 753	None	0.47A	4agdA-4otdA: 20.9	4agdA-4otdA: 26.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 ALA A 642 VAL A 675 CYH A 694 GLY A 697 LEU A 818 CYH A 828 PHE A 830	P30 A1001 (-3.8A) P30 A1001 (-3.4A) None None P30 A1001 (-3.4A) P30 A1001 (-4.6A) P30 A1001 (-4.1A) P30 A1001 (-3.9A)	0.36A	4agdA-4rt7A: 32.8	4agdA-4rt7A: 43.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LYS A 644 VAL A 675 GLY A 697 LEU A 818 CYH A 828 PHE A 830	P30 A1001 (-3.4A) None P30 A1001 (-3.4A) P30 A1001 (-4.6A) P30 A1001 (-4.1A) P30 A1001 (-3.9A)	0.66A	4agdA-4rt7A: 32.8	4agdA-4rt7A: 43.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	6	LEU A 14 ALA A 35 LYS A 37 VAL A 65 GLY A 87 LEU A 136	ACP A1264 ( 4.5A) ACP A1264 (-2.9A) None None ACP A1264 (-3.5A) ACP A1264 ( 4.8A)	0.77A	4agdA-4ueuA: 30.2	4agdA-4ueuA: 37.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 61 VAL A 92 PHE A 110 CYH A 111 GLY A 114 LEU A 162	6UI A 700 (-3.3A) None 6UI A 700 (-4.3A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A)	0.64A	4agdA-4usfA: 21.6	4agdA-4usfA: 25.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 40 ALA A 61 LYS A 63 PHE A 110 GLY A 114 LEU A 162	6UI A 700 ( 4.9A) 6UI A 700 (-3.3A) 6UI A 700 (-4.5A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A)	1.02A	4agdA-4usfA: 21.6	4agdA-4usfA: 25.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 40 ALA A 61 PHE A 110 CYH A 111 GLY A 114 LEU A 162	6UI A 700 ( 4.9A) 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A)	0.70A	4agdA-4usfA: 21.6	4agdA-4usfA: 25.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wbo	RHODOPSIN KINASE (Bos taurus)	PF00069 (Pkinase) PF00615 (RGS)	6	LEU A 193 ALA A 214 LYS A 216 VAL A 248 GLY A 270 LEU A 321	ANW A 601 ( 4.0A) ANW A 601 (-3.4A) None None ANW A 601 ( 4.5A) ANW A 601 (-4.9A)	0.76A	4agdA-4wboA: 16.8	4agdA-4wboA: 21.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 52 ALA A 72 VAL A 104 PHE A 128 CYH A 129 GLY A 132 LEU A 183 CYH A 193	KSA A 405 ( 4.0A) KSA A 405 (-3.2A) None KSA A 405 (-4.8A) KSA A 405 (-4.5A) KSA A 405 (-3.5A) KSA A 405 (-4.6A) KSA A 405 (-3.4A)	0.49A	4agdA-4wsqA: 22.1	4agdA-4wsqA: 24.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	6	LEU B 267 ALA B 288 LYS B 290 PHE B 336 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.68A	4agdA-4xeyB: 30.9	4agdA-4xeyB: 32.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	6	LEU B 267 ALA B 288 VAL B 318 PHE B 336 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 ( 4.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.56A	4agdA-4xeyB: 30.9	4agdA-4xeyB: 32.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 ALA A 642 VAL A 675 CYH A 694 GLY A 697 LEU A 818 CYH A 828 PHE A 830	P30 A1001 (-4.0A) P30 A1001 (-3.5A) None P30 A1001 (-4.2A) P30 A1001 (-3.5A) P30 A1001 (-4.3A) P30 A1001 (-4.8A) P30 A1001 ( 4.1A)	0.45A	4agdA-4xufA: 29.0	4agdA-4xufA: 51.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	6	LEU A 408 ALA A 428 LYS A 430 VAL A 458 GLY A 480 LEU A 528	746 A 702 (-3.8A) 746 A 702 (-2.4A) 746 A 702 (-3.7A) None 746 A 702 (-3.6A) 746 A 702 (-4.4A)	0.71A	4agdA-4y93A: 29.2	4agdA-4y93A: 27.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 484 ALA A 512 LYS A 514 VAL A 561 GLY A 567 LEU A 630	38O A1769 (-3.2A) 38O A1769 (-3.6A) 38O A1769 ( 3.1A) 38O A1769 (-4.3A) 38O A1769 (-3.4A) 38O A1769 (-4.6A)	0.49A	4agdA-5a46A: 34.7	4agdA-5a46A: 45.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ci7	SERINE/THREONINE-PRO TEIN KINASE ULK1 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 44 LYS A 46 VAL A 76 CYH A 95 GLY A 98 LEU A 145	51W A 401 (-3.4A) GOL A 404 ( 3.1A) None 51W A 401 (-3.9A) 51W A 401 (-3.7A) 51W A 401 (-4.5A)	0.55A	4agdA-5ci7A: 22.8	4agdA-5ci7A: 26.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5e8y	TGF-BETA RECEPTOR TYPE-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 275 LYS A 277 PHE A 327 GLY A 331 LEU A 386 CYH A 396	STU A 601 (-3.1A) STU A 601 (-2.4A) STU A 601 (-3.4A) STU A 601 (-3.5A) STU A 601 (-3.9A) STU A 601 (-3.2A)	0.77A	4agdA-5e8yA: 18.8	4agdA-5e8yA: 27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5eyk	AURORA KINASE B-A (Xenopus laevis)	PF00069 (Pkinase)	6	LEU A 99 ALA A 120 LYS A 122 PHE A 172 GLY A 176 LEU A 223	5U5 A 401 (-3.8A) 5U5 A 401 (-3.5A) 5U5 A 401 (-2.6A) 5U5 A 401 (-4.5A) 5U5 A 401 (-3.4A) 5U5 A 401 (-4.7A)	0.48A	4agdA-5eykA: 21.8	4agdA-5eykA: 25.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	LEU A 730 ALA A 756 VAL A 804 GLY A 810 LEU A 881	PP1 A2012 (-4.6A) PP1 A2012 (-3.2A) PP1 A2012 (-4.5A) PTR A 809 (-2.4A) PP1 A2012 (-4.6A)	0.52A	4agdA-5fm2A: 32.3	4agdA-5fm2A: 41.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 599 ALA A 625 VAL A 658 CYH A 677 GLY A 680 LEU A 825 CYH A 835 PHE A 837	748 A1001 (-3.8A) 748 A1001 (-3.7A) 748 A1001 ( 4.8A) 748 A1001 (-4.5A) 748 A1001 ( 4.0A) 748 A1001 (-4.3A) 748 A1001 (-4.5A) 748 A1001 (-3.7A)	0.46A	4agdA-5grnA: 41.0	4agdA-5grnA: 48.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 599 LYS A 627 VAL A 658 GLY A 680 LEU A 825 CYH A 835 PHE A 837	748 A1001 (-3.8A) 748 A1001 (-4.0A) 748 A1001 ( 4.8A) 748 A1001 ( 4.0A) 748 A1001 (-4.3A) 748 A1001 (-4.5A) 748 A1001 (-3.7A)	0.63A	4agdA-5grnA: 41.0	4agdA-5grnA: 48.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 57 ALA A 77 VAL A 109 CYH A 133 GLY A 136 LEU A 187 CYH A 197	IDV A 401 (-3.8A) IDV A 401 (-3.6A) None IDV A 401 (-4.6A) IDV A 401 (-3.4A) IDV A 401 (-4.4A) IDV A 401 (-3.6A)	0.63A	4agdA-5i3oA: 21.8	4agdA-5i3oA: 22.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 43 VAL A 74 PHE A 92 CYH A 93 GLY A 96 LEU A 143	6G2 A 901 (-3.2A) None 6G2 A 901 (-4.1A) TPO A 145 (-4.1A) 6G2 A 901 (-3.6A) 6G2 A 901 (-4.7A)	0.29A	4agdA-5j5tA: 20.1	4agdA-5j5tA: 21.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5jzn	SERINE/THREONINE-PRO TEIN KINASE DCLK1 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 417 LYS A 419 VAL A 449 GLY A 471 LEU A 518	GUI A 701 ( 3.9A) GUI A 701 (-3.1A) None GUI A 701 (-3.6A) GUI A 701 (-4.4A)	0.53A	4agdA-5jznA: 21.3	4agdA-5jznA: 25.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5l2r	FUMARATE HYDRATASE (Leishmania major)	PF05681 (Fumerase) PF05683 (Fumerase_C)	6	LEU A 489 ALA A 551 VAL A 389 VAL A 411 PHE A 549 LEU A 391	None	1.01A	4agdA-5l2rA: undetectable	4agdA-5l2rA: 21.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	ALA A 909 LYS A 911 VAL A 940 PHE A 958 GLY A 962 LEU A1016	ATP A1200 (-3.5A) ATP A1200 (-3.8A) None ATP A1200 ( 4.0A) ATP A1200 ( 4.0A) ATP A1200 (-4.6A)	0.71A	4agdA-5lpyA: 21.9	4agdA-5lpyA: 27.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpz	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	ALA A 909 LYS A 911 VAL A 940 PHE A 958 GLY A 962 LEU A1016	ADP A1200 (-3.5A) ADP A1200 ( 4.3A) None ADP A1200 (-4.1A) ADP A1200 ( 4.0A) ADP A1200 (-4.7A)	0.69A	4agdA-5lpzA: 21.8	4agdA-5lpzA: 26.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ncl	SERINE/THREONINE-PRO TEIN KINASE CBK1 (Saccharomyces cerevisiae)	no annotation	6	ALA A 379 LYS A 381 VAL A 413 PHE A 431 GLY A 435 LEU A 482	ANP A 801 ( 3.9A) ANP A 801 (-2.6A) ANP A 801 ( 4.9A) ANP A 801 ( 4.9A) None ANP A 801 (-4.8A)	0.73A	4agdA-5nclA: 17.8	4agdA-5nclA: 15.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	no annotation	5	ALA A 348 VAL A 379 PHE A 397 GLY A 401 LEU A 447	M77 A 601 ( 3.5A) None M77 A 601 (-4.1A) M77 A 601 ( 4.8A) M77 A 601 (-4.6A)	0.49A	4agdA-5vefA: 21.3	4agdA-5vefA: 26.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vil	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5 (Homo sapiens)	no annotation	5	LEU A 686 ALA A 707 VAL A 738 GLY A 760 LEU A 810	9E1 A1001 (-3.7A) 9E1 A1001 (-3.5A) 9E1 A1001 (-4.1A) 9E1 A1001 (-3.4A) 9E1 A1001 (-4.5A)	0.53A	4agdA-5vilA: 15.1	4agdA-5vilA: 12.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vo1	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 12 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 150 PHE A 192 CYH A 193 GLY A 196 LEU A 243	9FS A 501 (-3.4A) 9FS A 501 (-4.3A) 9FS A 501 (-4.3A) 9FS A 501 (-3.6A) 9FS A 501 (-4.7A)	0.46A	4agdA-5vo1A: 23.8	4agdA-5vo1A: 27.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5win	- (-)	no annotation	6	LEU A 551 LYS A 581 VAL A 610 PHE A 628 GLY A 632 LEU A 680	SKE A 901 (-3.4A) SKE A 901 ( 4.7A) SKE A 901 ( 4.7A) SKE A 901 (-3.6A) SKE A 901 (-3.1A) SKE A 901 (-4.1A)	0.68A	4agdA-5winA: 26.3	4agdA-5winA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xzw	SERINE/THREONINE-PRO TEIN KINASE RAD53 (Saccharomyces cerevisiae)	no annotation	5	ALA A 225 VAL A 257 PHE A 275 GLY A 279 LEU A 326	None	0.55A	4agdA-5xzwA: 18.6	4agdA-5xzwA: 22.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	6	LEU A 33 ALA A 54 VAL A 83 CYH A 102 GLY A 105 LEU A 153	ANP A 501 ( 3.8A) ANP A 501 ( 3.7A) None ANP A 501 (-4.2A) ANP A 501 ( 4.0A) ANP A 501 (-4.6A)	0.56A	4agdA-6ao5A: 21.0	4agdA-6ao5A: 22.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c7y	TYROSINE-PROTEIN KINASE JAK1 (Homo sapiens)	no annotation	6	LEU A 881 ALA A 906 VAL A 938 PHE A 958 GLY A 962 LEU A1010	ADP A1201 ( 4.5A) ADP A1201 (-3.4A) None None ADP A1201 ( 4.1A) ADP A1201 (-4.5A)	0.55A	4agdA-6c7yA: 27.0	4agdA-6c7yA: 13.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fdy	- (-)	no annotation	7	LEU U 20 ALA U 42 VAL U 75 PHE U 93 CYH U 94 GLY U 97 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.4A) DB8 U 301 (-4.2A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A)	0.76A	4agdA-6fdyU: 20.0	4agdA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fek	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	no annotation	5	LEU A 730 ALA A 756 VAL A 804 GLY A 810 LEU A 881	ADN A1104 ( 4.0A) ADN A1104 (-3.4A) ADN A1104 ( 4.6A) ADN A1104 ( 3.8A) ADN A1104 (-4.3A)	0.41A	4agdA-6fekA: 31.7	4agdA-6fekA: 23.72

[["4AGD_A_B49A2000_1","1h4l","Homo sapiens","CELL DIVISION PROTEIN KINASE 5","PF00069(Pkinase)",6,"ALA A  31;LYS A  33;VAL A  64;PHE A  82;CYH A  83;LEU A 133","None","0.57A","4agdA-1h4lA:16.9","4agdA-1h4lA:26.37"],["4AGD_A_B49A2000_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 267;ALA A 288;VAL A 318;PHE A 336;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 ( 4.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.35A","4agdA-1opkA:29.8","4agdA-1opkA:28.12"],["4AGD_A_B49A2000_1","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",8,"LEU A 616;ALA A 642;LYS A 644;VAL A 675;CYH A 694;GLY A 697;LEU A 818;CYH A 828","None","0.65A","4agdA-1rjbA:41.1","4agdA-1rjbA:47.80"],["4AGD_A_B49A2000_1","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",6,"LYS A 644;VAL A 675;GLY A 697;LEU A 818;CYH A 828;PHE A 830","None","1.26A","4agdA-1rjbA:41.1","4agdA-1rjbA:47.80"],["4AGD_A_B49A2000_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",6,"LEU A  78;ALA A  99;LYS A 101;GLY A 153;LEU A 201;CYH A 211","ATP A 535 (-3.9A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A);ATP A 535 ( 4.5A)","1.01A","4agdA-1s9iA:21.0","4agdA-1s9iA:25.00"],["4AGD_A_B49A2000_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",6,"LEU A  78;ALA A  99;VAL A 131;GLY A 153;LEU A 201;CYH A 211","ATP A 535 (-3.9A);ATP A 535 (-3.6A);5EA A1001 (-4.5A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A);ATP A 535 ( 4.5A)","0.84A","4agdA-1s9iA:21.0","4agdA-1s9iA:25.00"],["4AGD_A_B49A2000_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",5,"ALA A 389;VAL A 419;PHE A 437;GLY A 441;LEU A 489","None","0.51A","4agdA-1snxA:29.7","4agdA-1snxA:32.81"],["4AGD_A_B49A2000_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",9,"LEU A 595;ALA A 621;LYS A 623;VAL A 654;CYH A 673;GLY A 676;LEU A 799;CYH A 809;PHE A 811","STI A   3 ( 3.8A);STI A   3 (-3.5A);STI A   3 (-3.7A);STI A   3 (-4.3A);STI A   3 (-4.5A);STI A   3 ( 3.8A);STI A   3 (-4.4A);STI A   3 (-4.5A);STI A   3 (-3.6A)","0.65A","4agdA-1t46A:33.3","4agdA-1t46A:49.44"],["4AGD_A_B49A2000_1","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",5,"LEU A 344;ALA A 367;VAL A 399;GLY A 420;LEU A 468","STU A 100 (-3.8A);STU A 100 (-3.2A);None;STU A 100 (-3.5A);STU A 100 (-4.5A)","0.41A","4agdA-1u59A:30.5","4agdA-1u59A:30.34"],["4AGD_A_B49A2000_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",7,"LEU A  15;ALA A  36;LYS A  38;VAL A  68;CYH A  87;GLY A  90;LEU A 137","HYM A 400 (-4.2A);HYM A 400 (-3.5A);HYM A 400 (-3.2A);HYM A 400 (-4.8A);HYM A 400 (-4.2A);None;HYM A 400 (-4.5A)","0.58A","4agdA-1zltA:20.3","4agdA-1zltA:23.90"],["4AGD_A_B49A2000_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",5,"LEU X  17;ALA X  37;VAL X  67;GLY X  88;LEU X 137","STU X 902 (-3.8A);STU X 902 (-3.1A);None;STU X 902 (-3.5A);STU X 902 (-4.4A)","0.40A","4agdA-2dq7X:30.4","4agdA-2dq7X:32.93"],["4AGD_A_B49A2000_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 273;ALA A 293;VAL A 323;PHE A 340;GLY A 344;LEU A 393","QUE A   1 (-3.9A);QUE A   1 (-3.5A);None;QUE A   1 (-4.2A);QUE A   1 (-3.0A);QUE A   1 (-4.4A)","0.58A","4agdA-2hckA:27.8","4agdA-2hckA:30.69"],["4AGD_A_B49A2000_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",6,"LEU A 251;ALA A 271;VAL A 301;PHE A 318;GLY A 322;LEU A 371","1BM A 499 ( 3.7A);1BM A 499 (-3.6A);None;1BM A 499 (-4.1A);1BM A 499 (-3.5A);1BM A 499 (-4.4A)","0.63A","4agdA-2hk5A:29.9","4agdA-2hk5A:35.61"],["4AGD_A_B49A2000_1","2hw6","Homo sapiens","MAP KINASE-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 1","PF00069(Pkinase)",5,"LEU A  55;ALA A  76;GLY A 130;LEU A 177;CYH A 190","None","0.39A","4agdA-2hw6A:19.9","4agdA-2hw6A:24.94"],["4AGD_A_B49A2000_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",6,"ALA A 269;LYS A 271;VAL A 299;GLY A 321;LEU A 370;PHE A 382","GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-4.6A);None;GIN A 600 (-4.7A);GIN A 600 (-4.0A)","0.80A","4agdA-2hz0A:30.7","4agdA-2hz0A:35.55"],["4AGD_A_B49A2000_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",6,"ALA A 269;VAL A 299;PHE A 317;GLY A 321;LEU A 370;PHE A 382","GIN A 600 (-3.1A);GIN A 600 (-4.6A);GIN A 600 (-4.3A);None;GIN A 600 (-4.7A);GIN A 600 (-4.0A)","0.65A","4agdA-2hz0A:30.7","4agdA-2hz0A:35.55"],["4AGD_A_B49A2000_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",6,"LEU A 248;ALA A 269;LYS A 271;VAL A 299;GLY A 321;LEU A 370","GIN A 600 ( 4.6A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-4.6A);None;GIN A 600 (-4.7A)","0.62A","4agdA-2hz0A:30.7","4agdA-2hz0A:35.55"],["4AGD_A_B49A2000_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",6,"LEU A 248;ALA A 269;VAL A 299;PHE A 317;GLY A 321;LEU A 370","GIN A 600 ( 4.6A);GIN A 600 (-3.1A);GIN A 600 (-4.6A);GIN A 600 (-4.3A);None;GIN A 600 (-4.7A)","0.47A","4agdA-2hz0A:30.7","4agdA-2hz0A:35.55"],["4AGD_A_B49A2000_1","2j0j","Gallus gallus","FOCAL ADHESION KINASE 1","PF00373(FERM_M);PF07714(Pkinase_Tyr)",5,"ALA A 452;VAL A 484;CYH A 502;GLY A 505;LEU A 553","4ST A1687 (-3.3A);None;4ST A1687 (-4.1A);4ST A1687 (-3.2A);4ST A1687 (-4.4A)","0.53A","4agdA-2j0jA:32.5","4agdA-2j0jA:22.91"],["4AGD_A_B49A2000_1","2jkm","Gallus gallus","FOCAL ADHESION KINASE 1","PF07714(Pkinase_Tyr)",6,"ALA A 452;LYS A 454;VAL A 484;CYH A 502;GLY A 505;LEU A 553","BII A1687 (-3.5A);BII A1687 (-2.9A);None;BII A1687 (-4.1A);BII A1687 (-3.6A);BII A1687 (-4.2A)","0.64A","4agdA-2jkmA:31.3","4agdA-2jkmA:31.68"],["4AGD_A_B49A2000_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",7,"LEU A 588;ALA A 614;LYS A 616;VAL A 647;CYH A 666;GLY A 669;LEU A 785","None","0.48A","4agdA-2ogvA:27.4","4agdA-2ogvA:48.31"],["4AGD_A_B49A2000_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"LEU A 344;ALA A 367;LYS A 369;VAL A 399;GLY A 420;LEU A 468","ANP A 615 (-4.4A);ANP A 615 (-3.3A);ANP A 615 (-3.1A);None;ANP A 615 ( 3.9A);ANP A 615 (-4.7A)","0.87A","4agdA-2ozoA:22.4","4agdA-2ozoA:23.03"],["4AGD_A_B49A2000_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"LEU A 487;ALA A 515;LYS A 517;VAL A 564;GLY A 570;LEU A 633","None","0.48A","4agdA-2psqA:34.3","4agdA-2psqA:50.00"],["4AGD_A_B49A2000_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",6,"LEU A  68;ALA A  92;VAL A 125;PHE A 143;GLY A 147;LEU A 194","STU A   1 (-3.8A);STU A   1 (-3.3A);None;STU A   1 (-4.6A);STU A   1 ( 3.9A);STU A   1 (-4.6A)","0.47A","4agdA-2z7rA:16.1","4agdA-2z7rA:27.82"],["4AGD_A_B49A2000_1","2z8c","Homo sapiens","INSULIN RECEPTOR","PF07714(Pkinase_Tyr)",5,"LEU A1002;ALA A1028;LYS A1030;VAL A1060;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;S91 A   1 (-3.3A)","0.55A","4agdA-2z8cA:29.4","4agdA-2z8cA:36.47"],["4AGD_A_B49A2000_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"LEU A 253;ALA A 273;LYS A 275;VAL A 303;PHE A 321;GLY A 325;LEU A 374","None","0.83A","4agdA-2zv7A:29.9","4agdA-2zv7A:34.27"],["4AGD_A_B49A2000_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"LEU A 487;ALA A 515;LYS A 517;VAL A 564;GLY A 570;LEU A 633","M33 A1996 (-4.0A);M33 A1996 (-3.3A);M33 A1996 ( 4.5A);None;M33 A1996 ( 4.8A);M33 A1996 (-4.5A)","0.63A","4agdA-3b2tA:33.6","4agdA-3b2tA:49.01"],["4AGD_A_B49A2000_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"LEU A 484;ALA A 512;VAL A 561;GLY A 567;LEU A 630;PHE A 489","C4F A   1 ( 3.9A);C4F A   1 (-3.3A);C4F A   1 ( 4.8A);None;C4F A   1 (-4.6A);C4F A   1 (-3.7A)","0.78A","4agdA-3c4fA:33.5","4agdA-3c4fA:54.78"],["4AGD_A_B49A2000_1","3dko","Homo sapiens","EPHRIN TYPE-A RECEPTOR 7","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"ALA A 663;VAL A 695;PHE A 713;GLY A 717;LEU A 765;PHE A 777","IHZ A1001 (-3.3A);IHZ A1001 ( 4.9A);None;IHZ A1001 ( 3.9A);IHZ A1001 (-4.6A);IHZ A1001 (-4.7A)","0.61A","4agdA-3dkoA:31.1","4agdA-3dkoA:33.51"],["4AGD_A_B49A2000_1","3fzp","Homo sapiens","PROTEIN TYROSINE KINASE 2 BETA","PF07714(Pkinase_Tyr)",6,"LEU A 431;ALA A 455;LYS A 457;VAL A 487;GLY A 508;LEU A 556","AGS A 999 ( 4.4A);AGS A 999 (-3.6A);AGS A 999 (-2.5A);None;None;AGS A 999 (-4.5A)","0.80A","4agdA-3fzpA:30.5","4agdA-3fzpA:32.01"],["4AGD_A_B49A2000_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",9,"LEU A 833;ALA A 859;LYS A 861;VAL A 892;VAL A 909;CYH A 912;LEU A1029;CYH A1039;PHE A1041","8ST A2001 ( 4.7A);8ST A2001 ( 3.8A);8ST A2001 (-4.0A);8ST A2001 ( 4.7A);8ST A2001 (-4.1A);8ST A2001 (-3.8A);None;8ST A2001 (-4.2A);8ST A2001 ( 3.7A)","0.68A","4agdA-3hngA:41.4","4agdA-3hngA:67.22"],["4AGD_A_B49A2000_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",9,"LEU A 833;ALA A 859;VAL A 892;VAL A 909;CYH A 912;GLY A 915;LEU A1029;CYH A1039;PHE A1041","8ST A2001 ( 4.7A);8ST A2001 ( 3.8A);8ST A2001 ( 4.7A);8ST A2001 (-4.1A);8ST A2001 (-3.8A);None;None;8ST A2001 (-4.2A);8ST A2001 ( 3.7A)","0.60A","4agdA-3hngA:41.4","4agdA-3hngA:67.22"],["4AGD_A_B49A2000_1","3mi9","Homo sapiens","CELL DIVISION PROTEIN KINASE 9","PF00069(Pkinase)",6,"ALA A  46;LYS A  48;VAL A  79;PHE A 105;CYH A 106;LEU A 156","None","0.62A","4agdA-3mi9A:21.4","4agdA-3mi9A:25.60"],["4AGD_A_B49A2000_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",5,"LEU A 192;ALA A 213;VAL A 247;GLY A 269;LEU A 318","AMP A 577 ( 4.3A);AMP A 577 (-3.4A);None;None;AMP A 577 (-4.8A)","0.52A","4agdA-3nyoA:20.9","4agdA-3nyoA:22.03"],["4AGD_A_B49A2000_1","3q4t","Homo sapiens","ACTIVIN RECEPTOR TYPE-2A","PF00069(Pkinase)",5,"ALA A 217;LYS A 219;PHE A 269;GLY A 273;LEU A 329","TAK A   2 (-3.5A);TAK A   2 (-2.9A);TAK A   2 (-4.3A);TAK A   2 (-3.6A);TAK A   2 (-4.6A)","0.53A","4agdA-3q4tA:23.4","4agdA-3q4tA:24.42"],["4AGD_A_B49A2000_1","3q5i","Plasmodium berghei","PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",5,"LEU A  63;ALA A  84;PHE A 146;GLY A 150;LEU A 197","ANP A1634 ( 4.3A);ANP A1634 (-3.6A);ANP A1634 (-4.8A);None;ANP A1634 (-4.4A)","0.55A","4agdA-3q5iA:19.2","4agdA-3q5iA:22.57"],["4AGD_A_B49A2000_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",5,"LEU A 423;ALA A 443;VAL A 473;GLY A 495;LEU A 543","PP2 A   1 (-4.1A);PP2 A   1 (-3.2A);None;PP2 A   1 ( 4.2A);PP2 A   1 (-4.6A)","0.47A","4agdA-3sxsA:29.0","4agdA-3sxsA:32.40"],["4AGD_A_B49A2000_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",5,"LEU A 484;ALA A 512;VAL A 561;GLY A 567;LEU A 630","07J A   1 ( 4.3A);07J A   1 (-3.5A);07J A   1 (-4.7A);07J A   1 (-3.7A);07J A   1 ( 4.4A)","0.51A","4agdA-3tt0A:34.6","4agdA-3tt0A:50.26"],["4AGD_A_B49A2000_1","3v5q","Homo sapiens","NT-3 GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",5,"LEU A 544;ALA A 570;VAL A 601;GLY A 623;LEU A 686","0F4 A 902 ( 4.2A);0F4 A 902 (-3.2A);None;0F4 A 902 (-3.4A);0F4 A 902 (-4.5A)","0.52A","4agdA-3v5qA:26.6","4agdA-3v5qA:32.38"],["4AGD_A_B49A2000_1","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",9,"LEU A 840;ALA A 866;VAL A 899;VAL A 916;PHE A 918;CYH A 919;GLY A 922;LEU A1035;CYH A1045","4TT A2001 ( 4.0A);4TT A2001 (-3.5A);None;None;4TT A2001 (-4.5A);4TT A2001 (-4.3A);4TT A2001 (-3.7A);4TT A2001 (-4.8A);None","0.37A","4agdA-3vidA:38.8","4agdA-3vidA:85.96"],["4AGD_A_B49A2000_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",6,"LEU A  75;ALA A  96;LYS A  98;GLY A 150;LEU A 198;CYH A 208","ANP A 401 (-3.8A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A);CHU A 403 ( 3.7A)","1.29A","4agdA-3wigA:16.1","4agdA-3wigA:22.48"],["4AGD_A_B49A2000_1","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",9,"LEU A 840;ALA A 866;VAL A 899;VAL A 916;PHE A 918;CYH A 919;GLY A 922;LEU A1035;CYH A1045","LEV A1201 ( 3.8A);LEV A1201 (-3.5A);None;LEV A1201 ( 4.6A);LEV A1201 (-4.7A);LEV A1201 (-4.1A);LEV A1201 (-3.6A);LEV A1201 (-4.8A);GOL A1210 ( 3.3A)","0.33A","4agdA-3wzdA:37.6","4agdA-3wzdA:100.00"],["4AGD_A_B49A2000_1","4agu","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 1","PF00069(Pkinase)",6,"ALA A  31;LYS A  33;VAL A  64;CYH A  83;LEU A 133;CYH A 143","D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;D15 A 500 (-4.3A);D15 A 500 (-4.5A);D15 A 500 ( 4.0A)","0.61A","4agdA-4aguA:22.0","4agdA-4aguA:25.43"],["4AGD_A_B49A2000_1","4aw5","Homo sapiens","EPHRIN TYPE-B RECEPTOR 4","PF07714(Pkinase_Tyr)",5,"ALA A 121;LYS A 123;PHE A 171;GLY A 175;LEU A 223","30K A1365 (-3.2A);30K A1365 (-3.8A);30K A1365 (-4.4A);30K A1365 (-3.5A);30K A1365 (-4.5A)","0.54A","4agdA-4aw5A:26.3","4agdA-4aw5A:29.64"],["4AGD_A_B49A2000_1","4bc6","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 10","PF00069(Pkinase)",7,"LEU A  42;ALA A  63;VAL A  94;PHE A 112;CYH A 113;GLY A 116;LEU A 164","XZN A1317 (-3.6A);XZN A1317 (-3.5A);XZN A1317 (-4.4A);XZN A1317 (-4.5A);XZN A1317 (-3.7A);XZN A1317 ( 3.7A);XZN A1317 (-4.7A)","0.70A","4agdA-4bc6A:19.9","4agdA-4bc6A:25.33"],["4AGD_A_B49A2000_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",5,"LEU A 663;ALA A 684;VAL A 721;GLY A 743;LEU A 789","AGS A1985 (-4.2A);AGS A1985 (-3.5A);None;None;AGS A1985 (-4.8A)","0.43A","4agdA-4crsA:19.9","4agdA-4crsA:23.76"],["4AGD_A_B49A2000_1","4eut","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TBK1","PF00069(Pkinase)",6,"LEU A  15;ALA A  36;VAL A  68;PHE A  88;CYH A  89;GLY A  92","BX7 A 401 (-3.7A);BX7 A 401 (-3.4A);None;BX7 A 401 ( 4.6A);BX7 A 401 (-4.1A);BX7 A 401 (-3.5A)","0.40A","4agdA-4eutA:12.0","4agdA-4eutA:22.09"],["4AGD_A_B49A2000_1","4euu","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TBK1","PF00069(Pkinase)",6,"LEU A  15;ALA A  36;VAL A  68;PHE A  88;CYH A  89;GLY A  92","BX7 A 401 (-3.9A);BX7 A 401 (-3.4A);None;BX7 A 401 ( 4.6A);BX7 A 401 (-4.1A);BX7 A 401 (-3.3A)","0.41A","4agdA-4euuA:21.2","4agdA-4euuA:24.74"],["4AGD_A_B49A2000_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",6,"LEU A 377;ALA A 400;LYS A 402;VAL A 433;GLY A 454;LEU A 501","0SB A 701 ( 3.9A);0SB A 701 (-3.3A);0SB A 701 ( 4.8A);None;0SB A 701 (-3.5A);0SB A 701 (-4.4A)","0.83A","4agdA-4f4pA:29.4","4agdA-4f4pA:34.39"],["4AGD_A_B49A2000_1","4fie","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 4","PF00069(Pkinase);PF00786(PBD)",6,"ALA A 348;LYS A 350;VAL A 379;PHE A 397;GLY A 401;LEU A 447","ANP A1001 (-3.6A);ANP A1001 (-3.0A);None;ANP A1001 ( 4.6A);None;ANP A1001 (-4.7A)","0.72A","4agdA-4fieA:20.7","4agdA-4fieA:25.11"],["4AGD_A_B49A2000_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",5,"LEU A 377;ALA A 400;VAL A 433;GLY A 454;LEU A 501","ANP A 701 ( 4.6A);ANP A 701 (-3.3A);ANP A 701 (-4.8A);ANP A 701 ( 4.2A);ANP A 701 (-4.5A)","0.49A","4agdA-4fl3A:28.5","4agdA-4fl3A:23.11"],["4AGD_A_B49A2000_1","4fod","Homo sapiens","ALK TYROSINE KINASE RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A1122;ALA A1148;LYS A1150;VAL A1180;GLY A1202;LEU A1256","0UV A1501 (-3.8A);0UV A1501 (-3.4A);0UV A1501 (-3.7A);0UV A1501 ( 4.9A);0UV A1501 (-3.6A);0UV A1501 (-4.6A)","0.74A","4agdA-4fodA:29.7","4agdA-4fodA:33.43"],["4AGD_A_B49A2000_1","4fr4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 32A","PF00069(Pkinase)",5,"ALA A  50;VAL A  84;VAL A 100;GLY A 106;LEU A 153","STU A 401 (-3.2A);None;None;STU A 401 ( 3.7A);STU A 401 (-4.7A)","0.41A","4agdA-4fr4A:20.2","4agdA-4fr4A:23.31"],["4AGD_A_B49A2000_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",5,"LEU A 828;ALA A 853;VAL A 884;GLY A 908;LEU A 956","19S A1201 (-3.9A);19S A1201 (-3.3A);None;19S A1201 ( 3.8A);19S A1201 (-4.5A)","0.42A","4agdA-4hviA:29.2","4agdA-4hviA:31.32"],["4AGD_A_B49A2000_1","4idt","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14","PF00069(Pkinase)",6,"LEU A 406;ALA A 427;VAL A 453;GLY A 475;LEU A 522;CYH A 533","T28 A 701 (-3.8A);T28 A 701 (-3.0A);None;T28 A 701 ( 3.0A);T28 A 701 (-3.9A);T28 A 701 (-3.7A)","0.80A","4agdA-4idtA:21.2","4agdA-4idtA:26.84"],["4AGD_A_B49A2000_1","4jlc","Mus musculus","SERINE\/THREONINE-PROTEIN KINASE TBK1","PF00069(Pkinase)",6,"LEU A  15;ALA A  36;VAL A  68;PHE A  88;CYH A  89;GLY A  92","SU6 A 701 (-3.6A);SU6 A 701 (-3.4A);None;SU6 A 701 (-4.0A);SU6 A 701 (-3.8A);SU6 A 701 (-3.8A)","0.42A","4agdA-4jlcA:17.9","4agdA-4jlcA:20.61"],["4AGD_A_B49A2000_1","4jxf","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PLK4","PF00069(Pkinase)",5,"LEU A  18;ALA A  39;CYH A  92;GLY A  95;LEU A 143","631 A 301 (-3.4A);631 A 301 (-3.3A);631 A 301 (-4.5A);631 A 301 ( 3.7A);631 A 301 (-4.0A)","0.38A","4agdA-4jxfA:18.1","4agdA-4jxfA:23.76"],["4AGD_A_B49A2000_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",5,"LEU A 478;ALA A 506;VAL A 555;GLY A 561;LEU A 624","ACP A 801 (-3.8A);ACP A 801 (-3.3A);ACP A 801 (-4.7A);ACP A 801 ( 4.6A);ACP A 801 (-4.4A)","0.49A","4agdA-4k33A:34.2","4agdA-4k33A:51.55"],["4AGD_A_B49A2000_1","4ks8","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 6","PF00069(Pkinase)",5,"ALA A 434;VAL A 465;PHE A 483;GLY A 487;LEU A 533","B49 A 701 (-3.2A);None;B49 A 701 (-4.3A);B49 A 701 ( 3.7A);B49 A 701 (-4.5A)","0.43A","4agdA-4ks8A:21.9","4agdA-4ks8A:27.32"],["4AGD_A_B49A2000_1","4l01","Homo sapiens","TYROSINE-PROTEIN KINASE JAK1","PF07714(Pkinase_Tyr)",6,"LEU A 589;LYS A 622;VAL A 651;PHE A 669;GLY A 673;LEU A 721","None","0.77A","4agdA-4l01A:26.0","4agdA-4l01A:24.66"],["4AGD_A_B49A2000_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",6,"LEU A 273;ALA A 293;LYS A 295;VAL A 323;GLY A 344;LEU A 393","VGG A 601 (-3.2A);VGG A 601 (-3.5A);VGG A 601 (-3.8A);VGG A 601 ( 4.8A);VGG A 601 ( 3.2A);VGG A 601 (-4.5A)","0.83A","4agdA-4lggA:27.6","4agdA-4lggA:34.71"],["4AGD_A_B49A2000_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",8,"LEU A  46;ALA A  67;LYS A  69;VAL A  99;CYH A 126;GLY A 128;LEU A 180;CYH A 190","SIN A 401 ( 3.9A);SIN A 401 ( 3.7A);None;None;SIN A 401 (-4.3A);SIN A 401 (-3.5A);SIN A 401 ( 4.5A);None","0.82A","4agdA-4o38A:19.8","4agdA-4o38A:24.56"],["4AGD_A_B49A2000_1","4oav","Homo sapiens","PROTEIN (RNASE L)","PF00069(Pkinase);PF06479(Ribonuc_2-5A);PF12796(Ank_2);PF13857(Ank_5)",5,"ALA B 390;VAL B 418;VAL B 434;CYH B 437;LEU B 492","ACP B 801 (-3.2A);None;ACP B 801 (-4.8A);ACP B 801 (-4.5A);ACP B 801 (-4.5A)","0.55A","4agdA-4oavB:17.0","4agdA-4oavB:19.86"],["4AGD_A_B49A2000_1","4otd","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N1","PF00069(Pkinase);PF00433(Pkinase_C)",5,"LEU A 627;ALA A 648;VAL A 685;GLY A 707;LEU A 753","None","0.47A","4agdA-4otdA:20.9","4agdA-4otdA:26.78"],["4AGD_A_B49A2000_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",8,"LEU A 616;ALA A 642;VAL A 675;CYH A 694;GLY A 697;LEU A 818;CYH A 828;PHE A 830","P30 A1001 (-3.8A);P30 A1001 (-3.4A);None;None;P30 A1001 (-3.4A);P30 A1001 (-4.6A);P30 A1001 (-4.1A);P30 A1001 (-3.9A)","0.36A","4agdA-4rt7A:32.8","4agdA-4rt7A:43.33"],["4AGD_A_B49A2000_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",6,"LYS A 644;VAL A 675;GLY A 697;LEU A 818;CYH A 828;PHE A 830","P30 A1001 (-3.4A);None;P30 A1001 (-3.4A);P30 A1001 (-4.6A);P30 A1001 (-4.1A);P30 A1001 (-3.9A)","0.66A","4agdA-4rt7A:32.8","4agdA-4rt7A:43.33"],["4AGD_A_B49A2000_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",6,"LEU A  14;ALA A  35;LYS A  37;VAL A  65;GLY A  87;LEU A 136","ACP A1264 ( 4.5A);ACP A1264 (-2.9A);None;None;ACP A1264 (-3.5A);ACP A1264 ( 4.8A)","0.77A","4agdA-4ueuA:30.2","4agdA-4ueuA:37.79"],["4AGD_A_B49A2000_1","4usf","Homo sapiens","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase)",6,"ALA A  61;VAL A  92;PHE A 110;CYH A 111;GLY A 114;LEU A 162","6UI A 700 (-3.3A);None;6UI A 700 (-4.3A);6UI A 700 (-4.2A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A)","0.64A","4agdA-4usfA:21.6","4agdA-4usfA:25.78"],["4AGD_A_B49A2000_1","4usf","Homo sapiens","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase)",6,"LEU A  40;ALA A  61;LYS A  63;PHE A 110;GLY A 114;LEU A 162","6UI A 700 ( 4.9A);6UI A 700 (-3.3A);6UI A 700 (-4.5A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A)","1.02A","4agdA-4usfA:21.6","4agdA-4usfA:25.78"],["4AGD_A_B49A2000_1","4usf","Homo sapiens","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase)",6,"LEU A  40;ALA A  61;PHE A 110;CYH A 111;GLY A 114;LEU A 162","6UI A 700 ( 4.9A);6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 (-4.2A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A)","0.70A","4agdA-4usfA:21.6","4agdA-4usfA:25.78"],["4AGD_A_B49A2000_1","4wbo","Bos taurus","RHODOPSIN KINASE","PF00069(Pkinase);PF00615(RGS)",6,"LEU A 193;ALA A 214;LYS A 216;VAL A 248;GLY A 270;LEU A 321","ANW A 601 ( 4.0A);ANW A 601 (-3.4A);None;None;ANW A 601 ( 4.5A);ANW A 601 (-4.9A)","0.76A","4agdA-4wboA:16.8","4agdA-4wboA:21.21"],["4AGD_A_B49A2000_1","4wsq","Homo sapiens","AP2-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",8,"LEU A  52;ALA A  72;VAL A 104;PHE A 128;CYH A 129;GLY A 132;LEU A 183;CYH A 193","KSA A 405 ( 4.0A);KSA A 405 (-3.2A);None;KSA A 405 (-4.8A);KSA A 405 (-4.5A);KSA A 405 (-3.5A);KSA A 405 (-4.6A);KSA A 405 (-3.4A)","0.49A","4agdA-4wsqA:22.1","4agdA-4wsqA:24.38"],["4AGD_A_B49A2000_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",6,"LEU B 267;ALA B 288;LYS B 290;PHE B 336;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.68A","4agdA-4xeyB:30.9","4agdA-4xeyB:32.42"],["4AGD_A_B49A2000_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",6,"LEU B 267;ALA B 288;VAL B 318;PHE B 336;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 ( 4.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.56A","4agdA-4xeyB:30.9","4agdA-4xeyB:32.42"],["4AGD_A_B49A2000_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",8,"LEU A 616;ALA A 642;VAL A 675;CYH A 694;GLY A 697;LEU A 818;CYH A 828;PHE A 830","P30 A1001 (-4.0A);P30 A1001 (-3.5A);None;P30 A1001 (-4.2A);P30 A1001 (-3.5A);P30 A1001 (-4.3A);P30 A1001 (-4.8A);P30 A1001 ( 4.1A)","0.45A","4agdA-4xufA:29.0","4agdA-4xufA:51.75"],["4AGD_A_B49A2000_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",6,"LEU A 408;ALA A 428;LYS A 430;VAL A 458;GLY A 480;LEU A 528","746 A 702 (-3.8A);746 A 702 (-2.4A);746 A 702 (-3.7A);None;746 A 702 (-3.6A);746 A 702 (-4.4A)","0.71A","4agdA-4y93A:29.2","4agdA-4y93A:27.51"],["4AGD_A_B49A2000_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",6,"LEU A 484;ALA A 512;LYS A 514;VAL A 561;GLY A 567;LEU A 630","38O A1769 (-3.2A);38O A1769 (-3.6A);38O A1769 ( 3.1A);38O A1769 (-4.3A);38O A1769 (-3.4A);38O A1769 (-4.6A)","0.49A","4agdA-5a46A:34.7","4agdA-5a46A:45.43"],["4AGD_A_B49A2000_1","5ci7","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE ULK1","PF00069(Pkinase)",6,"ALA A  44;LYS A  46;VAL A  76;CYH A  95;GLY A  98;LEU A 145","51W A 401 (-3.4A);GOL A 404 ( 3.1A);None;51W A 401 (-3.9A);51W A 401 (-3.7A);51W A 401 (-4.5A)","0.55A","4agdA-5ci7A:22.8","4agdA-5ci7A:26.50"],["4AGD_A_B49A2000_1","5e8y","Homo sapiens","TGF-BETA RECEPTOR TYPE-2","PF07714(Pkinase_Tyr)",6,"ALA A 275;LYS A 277;PHE A 327;GLY A 331;LEU A 386;CYH A 396","STU A 601 (-3.1A);STU A 601 (-2.4A);STU A 601 (-3.4A);STU A 601 (-3.5A);STU A 601 (-3.9A);STU A 601 (-3.2A)","0.77A","4agdA-5e8yA:18.8","4agdA-5e8yA:27.55"],["4AGD_A_B49A2000_1","5eyk","Xenopus laevis","AURORA KINASE B-A","PF00069(Pkinase)",6,"LEU A  99;ALA A 120;LYS A 122;PHE A 172;GLY A 176;LEU A 223","5U5 A 401 (-3.8A);5U5 A 401 (-3.5A);5U5 A 401 (-2.6A);5U5 A 401 (-4.5A);5U5 A 401 (-3.4A);5U5 A 401 (-4.7A)","0.48A","4agdA-5eykA:21.8","4agdA-5eykA:25.94"],["4AGD_A_B49A2000_1","5fm2","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","PF07714(Pkinase_Tyr)",5,"LEU A 730;ALA A 756;VAL A 804;GLY A 810;LEU A 881","PP1 A2012 (-4.6A);PP1 A2012 (-3.2A);PP1 A2012 (-4.5A);PTR A 809 (-2.4A);PP1 A2012 (-4.6A)","0.52A","4agdA-5fm2A:32.3","4agdA-5fm2A:41.29"],["4AGD_A_B49A2000_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",8,"LEU A 599;ALA A 625;VAL A 658;CYH A 677;GLY A 680;LEU A 825;CYH A 835;PHE A 837","748 A1001 (-3.8A);748 A1001 (-3.7A);748 A1001 ( 4.8A);748 A1001 (-4.5A);748 A1001 ( 4.0A);748 A1001 (-4.3A);748 A1001 (-4.5A);748 A1001 (-3.7A)","0.46A","4agdA-5grnA:41.0","4agdA-5grnA:48.40"],["4AGD_A_B49A2000_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",7,"LEU A 599;LYS A 627;VAL A 658;GLY A 680;LEU A 825;CYH A 835;PHE A 837","748 A1001 (-3.8A);748 A1001 (-4.0A);748 A1001 ( 4.8A);748 A1001 ( 4.0A);748 A1001 (-4.3A);748 A1001 (-4.5A);748 A1001 (-3.7A)","0.63A","4agdA-5grnA:41.0","4agdA-5grnA:48.40"],["4AGD_A_B49A2000_1","5i3o","Homo sapiens","BMP-2-INDUCIBLE PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A  57;ALA A  77;VAL A 109;CYH A 133;GLY A 136;LEU A 187;CYH A 197","IDV A 401 (-3.8A);IDV A 401 (-3.6A);None;IDV A 401 (-4.6A);IDV A 401 (-3.4A);IDV A 401 (-4.4A);IDV A 401 (-3.6A)","0.63A","4agdA-5i3oA:21.8","4agdA-5i3oA:22.77"],["4AGD_A_B49A2000_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",6,"ALA A  43;VAL A  74;PHE A  92;CYH A  93;GLY A  96;LEU A 143","6G2 A 901 (-3.2A);None;6G2 A 901 (-4.1A);TPO A 145 (-4.1A);6G2 A 901 (-3.6A);6G2 A 901 (-4.7A)","0.29A","4agdA-5j5tA:20.1","4agdA-5j5tA:21.50"],["4AGD_A_B49A2000_1","5jzn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE DCLK1","PF00069(Pkinase)",5,"ALA A 417;LYS A 419;VAL A 449;GLY A 471;LEU A 518","GUI A 701 ( 3.9A);GUI A 701 (-3.1A);None;GUI A 701 (-3.6A);GUI A 701 (-4.4A)","0.53A","4agdA-5jznA:21.3","4agdA-5jznA:25.47"],["4AGD_A_B49A2000_1","5l2r","Leishmania major","FUMARATE HYDRATASE","PF05681(Fumerase);PF05683(Fumerase_C)",6,"LEU A 489;ALA A 551;VAL A 389;VAL A 411;PHE A 549;LEU A 391","None","1.01A","4agdA-5l2rA:undetectable","4agdA-5l2rA:21.08"],["4AGD_A_B49A2000_1","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",6,"ALA A 909;LYS A 911;VAL A 940;PHE A 958;GLY A 962;LEU A1016","ATP A1200 (-3.5A);ATP A1200 (-3.8A);None;ATP A1200 ( 4.0A);ATP A1200 ( 4.0A);ATP A1200 (-4.6A)","0.71A","4agdA-5lpyA:21.9","4agdA-5lpyA:27.71"],["4AGD_A_B49A2000_1","5lpz","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",6,"ALA A 909;LYS A 911;VAL A 940;PHE A 958;GLY A 962;LEU A1016","ADP A1200 (-3.5A);ADP A1200 ( 4.3A);None;ADP A1200 (-4.1A);ADP A1200 ( 4.0A);ADP A1200 (-4.7A)","0.69A","4agdA-5lpzA:21.8","4agdA-5lpzA:26.92"],["4AGD_A_B49A2000_1","5ncl","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE CBK1","no annotation",6,"ALA A 379;LYS A 381;VAL A 413;PHE A 431;GLY A 435;LEU A 482","ANP A 801 ( 3.9A);ANP A 801 (-2.6A);ANP A 801 ( 4.9A);ANP A 801 ( 4.9A);None;ANP A 801 (-4.8A)","0.73A","4agdA-5nclA:17.8","4agdA-5nclA:15.14"],["4AGD_A_B49A2000_1","5vef","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 4","no annotation",5,"ALA A 348;VAL A 379;PHE A 397;GLY A 401;LEU A 447","M77 A 601 ( 3.5A);None;M77 A 601 (-4.1A);M77 A 601 ( 4.8A);M77 A 601 (-4.6A)","0.49A","4agdA-5vefA:21.3","4agdA-5vefA:26.01"],["4AGD_A_B49A2000_1","5vil","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5","no annotation",5,"LEU A 686;ALA A 707;VAL A 738;GLY A 760;LEU A 810","9E1 A1001 (-3.7A);9E1 A1001 (-3.5A);9E1 A1001 (-4.1A);9E1 A1001 (-3.4A);9E1 A1001 (-4.5A)","0.53A","4agdA-5vilA:15.1","4agdA-5vilA:12.31"],["4AGD_A_B49A2000_1","5vo1","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 12","PF07714(Pkinase_Tyr)",5,"ALA A 150;PHE A 192;CYH A 193;GLY A 196;LEU A 243","9FS A 501 (-3.4A);9FS A 501 (-4.3A);9FS A 501 (-4.3A);9FS A 501 (-3.6A);9FS A 501 (-4.7A)","0.46A","4agdA-5vo1A:23.8","4agdA-5vo1A:27.41"],["4AGD_A_B49A2000_1","5win","-","-","no annotation",6,"LEU A 551;LYS A 581;VAL A 610;PHE A 628;GLY A 632;LEU A 680","SKE A 901 (-3.4A);SKE A 901 ( 4.7A);SKE A 901 ( 4.7A);SKE A 901 (-3.6A);SKE A 901 (-3.1A);SKE A 901 (-4.1A)","0.68A","4agdA-5winA:26.3","4agdA-5winA:undetectable"],["4AGD_A_B49A2000_1","5xzw","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE RAD53","no annotation",5,"ALA A 225;VAL A 257;PHE A 275;GLY A 279;LEU A 326","None","0.55A","4agdA-5xzwA:18.6","4agdA-5xzwA:22.96"],["4AGD_A_B49A2000_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",6,"LEU A  33;ALA A  54;VAL A  83;CYH A 102;GLY A 105;LEU A 153","ANP A 501 ( 3.8A);ANP A 501 ( 3.7A);None;ANP A 501 (-4.2A);ANP A 501 ( 4.0A);ANP A 501 (-4.6A)","0.56A","4agdA-6ao5A:21.0","4agdA-6ao5A:22.40"],["4AGD_A_B49A2000_1","6c7y","Homo sapiens","TYROSINE-PROTEIN KINASE JAK1","no annotation",6,"LEU A 881;ALA A 906;VAL A 938;PHE A 958;GLY A 962;LEU A1010","ADP A1201 ( 4.5A);ADP A1201 (-3.4A);None;None;ADP A1201 ( 4.1A);ADP A1201 (-4.5A)","0.55A","4agdA-6c7yA:27.0","4agdA-6c7yA:13.88"],["4AGD_A_B49A2000_1","6fdy","-","-","no annotation",7,"LEU U  20;ALA U  42;VAL U  75;PHE U  93;CYH U  94;GLY U  97;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.4A);DB8 U 301 (-4.2A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A)","0.76A","4agdA-6fdyU:20.0","4agdA-6fdyU:undetectable"],["4AGD_A_B49A2000_1","6fek","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","no annotation",5,"LEU A 730;ALA A 756;VAL A 804;GLY A 810;LEU A 881","ADN A1104 ( 4.0A);ADN A1104 (-3.4A);ADN A1104 ( 4.6A);ADN A1104 ( 3.8A);ADN A1104 (-4.3A)","0.41A","4agdA-6fekA:31.7","4agdA-6fekA:23.72"]]